Nureca

Chandigarh, India Founded: 2016 • Age: 10 yrs Listed
Health and wellness devices are manufactured by Nureca in India.
Request Access
Report Incorrect Data
Page last updated

About Nureca

Nureca is a publicly listed company based in Chandigarh (India) founded in 2016 by Aryan Goyal. Health and wellness devices are manufactured by Nureca in India. The company has 271 employees. Its website nureca.com draws about 21 thousand monthly visits. Its Indian entity Nureca Limited reported revenue of ₹155 Cr. Nureca offers products and services including BP Monitor, Pulse Oximeter, Glucose Meter, and Fitness Tracker. Its focus areas include HealthTech, Healthcare Booking Platforms, Pharmacies and Medical Devices. Its competitors include Lifegaurd, Coronation Life and ClickOnCare.

Company details

Nureca was founded in 2016 in Chandigarh, India, by Aryan Goyal. Operations are focused on the health and wellness sector, where various devices are produced for consumer use. Manufacturing activities are conducted primarily in India, with the companys domain nureca.com supporting online accessibility. The firm maintains a presence in the domestic market, emphasizing device production without broader service offerings noted.

  • Headquarters Chandigarh, India
  • Employees 271
  • Founders Aryan Goyal
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website nureca.com
  • Social LinkedIn Facebook YouTube
  • Legal Name Nureca Ltd.
Operational Areas
Healthcare → Digital Health & Telemedicine
Key Metrics
  • Market Cap
    ₹287 Cr

    NURECA · NSE

  • Share Price
    ₹302.90

    +0.80% today

  • Revenue
    ₹147 Cr

    FY 2025-26 · +34.0% YoY

  • EBITDA
    ₹0.16 Cr

    Margin 0.1%

  • Net Profit
    ₹2.08 Cr

    FY 2025-26 · +170.1% YoY

  • P/E (TTM)
    59.7x

    P/B 1.5x

  • ROE
    1.1%

    ROCE 3.3%

  • Debt / Equity
    0.02

    Interest cover -68.8x

  • Employee Count
    271

Products & Services of Nureca

Nureca offers a comprehensive portfolio of products and services, including BP Monitor, Pulse Oximeter, Glucose Meter, and Fitness Tracker.

BP Monitor
Health Monitoring

Device for accurate blood pressure measurement and tracking.

Pulse Oximeter
Health Monitoring

Tool to measure oxygen levels and pulse rate effectively.

Glucose Meter
Health Monitoring

Portable device for blood sugar level testing.

Fitness Tracker
Wellness Devices

Wearable for tracking activity and health metrics.

Apps and channels of Nureca

its YouTube channel Dr Trust (Nureca) has 30.4K subscribers and 30 videos.

Dr Trust (Nureca)
YouTube 30.4K subscribers 30 videos Science & Technology
Open channel

Videos from Nureca

The most watched videos on Nureca's YouTube channel, Dr Trust (Nureca) (30.4K subscribers). Click a video to play it here.

Rohit Sharma’s Secret to Stress Relief? Dr Physio Head & Scalp Massager 1036
21.3K views
Dr Physio Supervolt PRO Gun Massager 1043 – Rohit Sharma’s pick for deep muscle relief
18.2K views
Rohit Sharma Calls It the Best Squeezing Massager! Dr Physio USA Neck, Shoulder & Back Massager 1048
17.8K views
Rohit Sharma’s Leg Recovery Routine with Dr Physio USA Bliss Shiatsu Electric Foot Massager 1045
15.7K views

More on Dr Trust (Nureca).

Board of directors of Nureca Limited (Nureca)

Nureca Limited is the primary company behind Nureca. The board of Nureca Limited currently have 8 directors; the longest-serving is Saurabh Goyal, appointed in 2017. 11 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Saurabh Goyal
DIN 00136037
Managing Director11 Feb 20179 yrs 8 moNureca Limited
Charu Singh
DIN 07822158
Director21 Oct 20206 yrsNureca Limited
Vijay Kumar Sharma
DIN 02449088
Director21 Oct 20206 yrsNureca Limited
Ruchita Agarwal
DIN 08941249
Director29 Oct 20206 yrsNureca Limited
Rajinder Sharma
DIN 00317133
Whole-time director28 May 20224 yrs 5 moNureca Limited
Rupinder Tewari
DIN 07009485
Director01 Jan 20251 yr 9 moNureca Limited
Kuldip Kumar Bhasin
DIN 09250008
Director01 Jan 20251 yr 9 moNureca Limited
Smita Goyal
DIN 08929179
Whole-time director01 Jun 20264 moNureca Limited

People of Nureca

7 people are tracked at Nureca (2 in leadership, 5 in team); the tracked headcount is 271.

NameRoleGroup
Aryan Goyal
FounderLeadership
Saurabh Goyal
Managing DirectorLeadership
M.D. Amir Mirza
Ecommerce ManagerTeam
Nandini Singh
Officer- Talent AcquisitionTeam
Aman Sharma
Senior Executive Human ResourcesTeam
Rita G Chauhan
Marketing & Promotion Content CreatorTeam
Atul Kumar
Graphic DesignerTeam
Premium access

Complete people profiles for Nureca

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Nureca

Nureca is a publicly listed company on the NSE with ticker symbol NURECA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date25 Feb 2021
  • Listed onBSE: 543264 · NSE: NURECA
  • Listed entityNureca Ltd.
  • Exchange sectorHealth technology
  • ISININE0DSF01015
  • Share price₹327.90 (+1.39% on the day) · 2026-10-14
  • Market capitalisation₹311 Cr
  • Price to earnings78.2
  • EPS (diluted, trailing year)₹4.19
  • Volume (last session)2,456

Financials of Nureca

Exchange-reported figures of Nureca Limited, the listed company behind Nureca (NSE: NURECA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹147 Cr
+34.0% YoY
EBITDA
₹0.16 Cr
+102.1% YoY
Profit After Tax
₹2.08 Cr
+170.1% YoY
Net Worth
₹181 Cr
-7.0% YoY
Total Assets
₹184 Cr
-8.1% YoY
Total Debt
₹2.26 Cr
-54.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14711091.9311125621399.43
Revenue growth+34.0%+19.3%-17.4%-56.4%+19.7%+114.7%-
EBITDA0.16(7.54)(10.21)(15.02)55.5161.539.68
EBITDA margin+0.1%-6.9%-11.1%-13.5%+21.7%+28.8%+9.7%
Profit before tax4.961.35(2.55)(10.75)60.9962.338.60
Net profit2.080.77(6.11)(10.70)44.4946.376.38
Net profit margin+1.4%+0.7%-6.7%-9.6%+17.4%+21.7%+6.4%
EPS (₹)2.180.85(1.79)(8.25)44.9646.376,395.00
Balance sheet
Total assets18420019719920816724.81
Net worth18119419319520316314.93
Total debt2.264.972.523.334.413.899.78
Cash & bank41.4212745.3070.9784.351270.07
Net working capital10117990.4012016216323.68
Cash flow
Cash from operations3.30(19.08)(2.71)10.231.4034.87(7.92)
Cash from investing14.498.4317.57(16.47)(3.09)(110)(0.39)
Cash from financing(19.56)(0.17)(1.30)(1.51)(7.30)92.348.28
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.5340.3435.4139.6437.7434.1831.7426.46
Revenue growth (YoY)+55.1%+18.0%+11.6%+49.8%+21.0%+68.6%--
Other income1.351.821.022.192.322.571.991.48
EBITDA5.233.42(5.78)3.253.27(0.56)1.20(4.02)
EBITDA margin+8.9%+8.5%-16.3%+8.2%+8.7%-1.6%+3.8%-15.2%
Depreciation0.810.610.450.500.540.530.520.54
Interest0.260.200.300.280.460.250.620.18
Profit before tax5.514.43(5.51)4.664.591.232.05(3.26)
Tax1.461.370.590.930.970.42(0.41)(0.45)
Net profit4.053.06(6.10)3.733.620.812.46(2.81)
EPS (₹)4.253.21(6.45)3.913.630.812.47(2.80)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14711510311727022599.43
Revenue growth+28.4%+11.8%-12.5%-56.6%+20.2%+126.1%-
EBITDA(2.61)(9.74)(11.14)(15.39)55.7861.689.70
EBITDA margin-1.8%-8.5%-10.9%-13.1%+20.7%+27.4%+9.8%
Profit before tax2.83(0.47)(3.28)(10.95)61.3462.498.62
Net profit0.29(0.77)(2.45)(8.16)44.8446.536.40
Net profit margin+0.2%-0.7%-2.4%-7.0%+16.6%+20.7%+6.4%
EPS (₹)0.31(0.67)(2.44)(8.42)45.3146.536,410.00
Balance sheet
Total assets18019719619920816824.78
Net worth17719219319520416314.97
Total debt2.214.112.433.254.333.819.70
Cash & bank41.3512745.2070.8684.191260.04
Net working capital96.0417487.3711816116223.61
Cash flow
Cash from operations0.32(18.82)(3.00)12.051.8335.10(7.85)
Cash from investing16.508.8317.84(18.30)(3.37)(110)(0.39)
Cash from financing(18.61)(0.79)(1.28)(1.51)(7.30)92.348.20
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.6040.4035.4139.6437.8434.3231.7527.21
Revenue growth (YoY)+54.9%+17.7%+11.5%+45.7%+16.9%+47.2%--
Other income1.421.921.062.292.382.592.001.52
Total expenses54.0537.9541.9537.2535.2235.4031.1831.94
EBITDA4.552.45(6.54)2.392.62(1.08)0.57(4.73)
EBITDA margin+7.8%+6.1%-18.5%+6.0%+6.9%-3.1%+1.8%-17.4%
Depreciation0.760.570.430.460.480.480.480.49
Interest0.220.180.240.180.410.200.590.14
Profit before tax4.993.62(6.15)4.044.110.831.50(3.84)
Tax1.371.190.480.820.970.28(0.58)(0.56)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.5340.3435.4139.6437.7434.1831.7426.46
Revenue growth (YoY)+55.1%+18.0%+11.6%+49.8%+21.0%+68.6%--
Other income1.351.821.022.192.322.571.991.48
EBITDA5.233.42(5.78)3.253.27(0.56)1.20(4.02)
EBITDA margin+8.9%+8.5%-16.3%+8.2%+8.7%-1.6%+3.8%-15.2%
Depreciation0.810.610.450.500.540.530.520.54
Interest0.260.200.300.280.460.250.620.18
Profit before tax5.514.43(5.51)4.664.591.232.05(3.26)
Tax1.461.370.590.930.970.42(0.41)(0.45)
Net profit4.053.06(6.10)3.733.620.812.46(2.81)
EPS (₹)4.253.21(6.45)3.913.630.812.47(2.80)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14711091.9311125621399.43
Revenue growth+34.0%+19.3%-17.4%-56.4%+19.7%+114.7%-
Other income8.1012.4410.517.117.702.820.06
Total expenses14711710212620015289.75
Employee cost17.0415.3112.2016.069.914.583.16
EBITDA0.16(7.54)(10.21)(15.02)55.5161.539.68
EBITDA margin+0.1%-6.9%-11.1%-13.5%+21.7%+28.8%+9.7%
Depreciation2.022.342.362.391.480.420.37
Interest1.281.210.490.450.741.600.77
Profit before tax4.961.35(2.55)(10.75)60.9962.338.60
Tax2.900.49(0.75)(2.49)16.0215.962.22
Net profit2.080.77(6.11)(10.70)44.4946.376.38
Net profit margin+1.4%+0.7%-6.7%-9.6%+17.4%+21.7%+6.4%
EPS (₹)2.180.85(1.79)(8.25)44.9646.376,395.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.5410.0010.0010.0010.0010.000.01
Reserves & surplus17118418318519315314.92
Shareholders' funds (net worth)18119419319520316314.93
Minority interest0.000.000.000.000.000.000.00
Secured loans0.692.250.400.000.000.000.00
Unsecured loans1.572.722.123.334.413.899.78
Total debt2.264.972.523.334.413.899.78
Total liabilities18420019719920816724.81
Assets
Gross block19.7714.3210.1910.5911.874.491.46
Net block13.589.007.118.6510.183.681.06
Capital work in progress0.000.000.270.000.420.300.00
Investments1.011.0493.6359.0933.190.000.00
Inventories47.5139.9230.8534.4863.1836.7816.43
Sundry debtors7.753.321.624.302.893.7012.90
Cash & bank balances41.4212745.3070.9784.351270.07
Loans & advances16.9918.2821.1917.7422.5813.953.35
Total current assets11418998.9612717318132.75
Total current liabilities12.3410.038.567.5911.1218.329.07
Net working capital10117990.4012016216323.68
Total assets18420019719920816724.81
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.2414.060.508.2517.240.070.11
Net cash from operating activities3.30(19.08)(2.71)10.231.4034.87(7.92)
Net cash from investing activities14.498.4317.57(16.47)(3.09)(110)(0.39)
Net cash from financing activities(19.56)(0.17)(1.30)(1.51)(7.30)92.348.28
Net change in cash(1.78)(10.82)13.56(7.75)(8.99)17.17(0.04)
Closing cash41.4212745.3070.9784.351270.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+34.0%+19.3%-17.4%-56.4%+19.7%+114.7%-
EBITDA growth+102.1%+26.2%+32.0%-127.1%-9.8%+535.6%-
PBT growth+267.4%+9998.0%+76.3%--2.2%+624.8%-2.8%
Net income growth+170.1%+112.6%+42.9%-124.1%-4.1%+626.8%-
Revenue CAGR (3Y)+9.7%-24.6%-24.5%+3.8%+60.4%--
EBITDA CAGR (3Y)----+83.0%--
Profitability & leverage
Net income margin+1.4%+0.8%-2.0%-7.4%+17.6%+21.7%+6.4%
Return on capital employed+3.3%+1.3%-4.0%-6.3%+32.9%+66.9%+60.1%
Return on net worth+1.1%+0.4%-3.1%-5.4%+24.6%+52.4%+61.2%
Debt / equity0.020.020.020.020.020.080.49
Long-term debt / equity0.010.010.010.010.020.070.48
Interest cover-68.82-12.25-3.90-2.581.372.628.27
Efficiency & per share
Fixed asset turnover8.628.958.859.9131.2486.072,209.56
Inventory turnover3.363.102.812.285.118.026.63
Debtors turnover26.5544.4031.0630.9777.5625.729.14
EPS (₹)2.180.85(1.79)(8.25)44.9646.376,395.00
Dividend per share (₹)0.000.000.000.003.002.000.00
Book value per share (₹)189.44194.29193.11194.88203.20163.1013,944.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.6040.4035.4139.6437.8434.3231.7527.21
Revenue growth (YoY)+54.9%+17.7%+11.5%+45.7%+16.9%+47.2%--
Other income1.421.921.062.292.382.592.001.52
Total expenses54.0537.9541.9537.2535.2235.4031.1831.94
EBITDA4.552.45(6.54)2.392.62(1.08)0.57(4.73)
EBITDA margin+7.8%+6.1%-18.5%+6.0%+6.9%-3.1%+1.8%-17.4%
Depreciation0.760.570.430.460.480.480.480.49
Interest0.220.180.240.180.410.200.590.14
Profit before tax4.993.62(6.15)4.044.110.831.50(3.84)
Tax1.371.190.480.820.970.28(0.58)(0.56)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14711510311727022599.43
Revenue growth+28.4%+11.8%-12.5%-56.6%+20.2%+126.1%-
Other income8.3212.5410.567.177.722.820.06
Total expenses15012411413321416389.73
Employee cost15.4314.3611.5715.519.834.583.16
EBITDA(2.61)(9.74)(11.14)(15.39)55.7861.689.70
EBITDA margin-1.8%-8.5%-10.9%-13.1%+20.7%+27.4%+9.8%
Depreciation1.852.152.242.301.430.410.37
Interest1.031.120.460.430.731.600.77
Profit before tax2.83(0.47)(3.28)(10.95)61.3462.498.62
Tax2.540.21(0.83)(2.54)16.0215.962.22
Net profit0.29(0.77)(2.45)(8.16)44.8446.536.40
Net profit margin+0.2%-0.7%-2.4%-7.0%+16.6%+20.7%+6.4%
EPS (₹)0.31(0.67)(2.44)(8.42)45.3146.536,410.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.5410.0010.0010.0010.0010.000.01
Reserves & surplus16818218318519415314.96
Shareholders' funds (net worth)17719219319520416314.97
Secured loans0.671.520.400.000.000.000.00
Unsecured loans1.542.592.033.254.333.819.70
Total debt2.214.112.433.254.333.819.70
Total liabilities18019719619920816824.78
Assets
Gross block17.8512.669.159.8710.484.161.44
Net block12.297.796.338.089.783.371.07
Capital work in progress0.000.000.000.000.420.300.00
Investments4.064.1096.6962.1434.490.820.05
Inventories45.4135.5528.7632.8363.1736.7816.43
Sundry debtors9.784.531.814.272.870.2312.90
Cash & bank balances41.3512745.2070.8684.191260.04
Loans & advances12.9215.9219.7416.9622.3117.303.32
Total current assets10918395.5112517318132.69
Total current liabilities13.428.918.147.4011.0518.339.08
Net working capital96.0417487.3711816116223.61
Total assets18019719619920816824.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.1913.960.408.1617.000.040.08
Net cash from operating activities0.32(18.82)(3.00)12.051.8335.10(7.85)
Net cash from investing activities16.508.8317.84(18.30)(3.37)(110)(0.39)
Net cash from financing activities(18.61)(0.79)(1.28)(1.51)(7.30)92.348.20
Net change in cash(1.79)(10.77)13.56(7.76)(8.84)16.96(0.05)
Closing cash41.3512745.2070.8684.191260.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+28.4%+11.8%-12.5%-56.6%+20.2%+126.1%-
EBITDA growth+73.2%+12.6%+27.6%-127.6%-9.6%+535.9%-
PBT growth+9998.0%+85.7%+70.1%--1.8%+624.9%-
Net income growth+137.7%+68.6%+70.0%-118.2%-3.6%+627.0%-
Revenue CAGR (3Y)+7.9%-24.9%-23.0%+5.6%+617.9%+625.0%+1606.7%
EBITDA CAGR (3Y)-44.7%---+1017.2%+1355.6%-
Profitability & leverage
Net income margin+0.2%-0.6%-2.4%-7.2%+16.8%+20.7%+6.4%
Return on capital employed+2.1%+0.3%-1.4%-5.2%+33.0%+66.7%+75.6%
Return on net worth+0.2%-0.4%-1.3%-4.2%+24.7%+52.2%+85.4%
Debt / equity0.020.020.010.020.020.080.65
Long-term debt / equity0.010.010.010.010.020.070.62
Interest cover-23.09-9.42-3.44-2.431.342.618.25
Efficiency & per share
Fixed asset turnover9.6510.5110.7811.5136.9080.30132.57
Inventory turnover3.643.573.332.445.418.4511.51
Debtors turnover20.5736.1633.7432.82174.2834.2515.26
EPS (₹)0.31(0.67)(2.44)(8.42)45.3146.536,410.00
Dividend per share (₹)0.000.000.000.003.002.000.00
Book value per share (₹)185.66192.48192.86195.26203.74163.2914,970.00

Competitors of Nureca

Nureca has 3 listed competitors in our database. They include Lifegaurd, Coronation Life and ClickOnCare.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Lifegaurd
lifeguard-med.com2010Chandigarh, India
An online platform for healthcare products is provided by Lifegaurd.
Coronation Life
coronationlife.com2022Delhi, India18
Manufactures and sells health products like hot water bottles and medical devices.
ClickOnCare
clickoncare.com2013Bengaluru, India8
An online retail store for healthcare, wellness, and fitness products.
Premium access

Detailed competitors of Nureca

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Nureca

The website of Nureca (nureca.com) receives about 21.1K visits a month.

  • Monthly visits
    21.1K

    ▲ 78.6% vs previous month

Top companies in Digital Health & Telemedicine

3 companies that operate in the same segment as Nureca (Digital Health & Telemedicine) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Tata 1mg
Provider of an online pharmacy with doctor listing and teleconsultation services
2015Delhi, Delhi, IndiaUSD 199.65 MUSD 328.97 M5,212
MediBuddy
Online platform offering multiple healthcare services
2013Bengaluru, Karnataka, IndiaUSD 199.22 MUSD 62.4 M52
SastaSundar
An online marketplace for healthcare products is operated.
2011Kolkata, West Bengal, IndiaUSD 38.26 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Nureca

India's Nureca hits near three-month high on Q3 profit jump
Reuters • 9 months ago
Nureca Approves Buyback Worth Up To 191.4 Mln Rupees
Reuters • 11 months ago
Nureca Limited Reports 18.28 percent Growth for Q3 FY25, Releases Strategic Plan for FY26
Aninews • 1 year ago
Nureca enters into distribution agreement with Zepto
Sharesbazaar • 1 year ago
Nureca Ltd appoints Vivek Gupta as chief officer sales
Fashionnetwork • 1 year ago
Nureca Acquires Shares Of Yes Bank For 9.7 Million Rupees
Reuters • 1 year ago
Nureca Acquires Shares Of IndusInd Bank Worth 15 Mln Rupees
Reuters • 1 year ago
India's Nureca gains on distribution deal with Zepto
Reuters • 1 year ago
Nureca signs distribution agreement with Zepto
Moneycontrol • 1 year ago
Nureca Standalone September 2024 Net Sales at Rs 32.37 crore, up 3.24% Y-o-Y
Moneycontrol • 2 years ago
Premium access

Complete news archive for Nureca

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nureca

Nureca was founded in 2016.

Nureca is headquartered in Chandigarh, India.

Nureca has 271 employees.

The primary company behind Nureca, Nureca Limited, reported revenue of ₹155 Cr for FY 2026, up 34% year on year.

Nureca was founded in 2016 in Chandigarh, India, by Aryan Goyal. Operations are focused on the health and wellness sector, where various devices are produced for consumer use. Manufacturing activities are conducted primarily in India, with the companys domain nureca.com supporting online accessibility. The firm maintains a presence in the domestic market, emphasizing device production without broader service offerings noted.

Nureca's top competitors include Lifegaurd, ClickOnCare and Coronation Life.

Nureca offers BP Monitor, Pulse Oximeter, Glucose Meter, and Fitness Tracker.

Yes, Nureca is publicly traded on NSE under the ticker symbol NURECA.

Nureca operates through Nureca Limited.

The legal entities of Nureca currently have 10 directors, including Smita Goyal, Saurabh Goyal, Charu Singh and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available